Summary
Back pain due to vertebral collapse is the main symptom of postmenopausal osteoporosis. The clinical picture in these crush fractures varies, depending on the type and the location of fracture, but in general, a new vertebral crush fracture gives rise to severe pain that immobilizes the patient and necessitates bedrest. In this double-blind controlled clinical trial, 56 patients who had recently (within the last 3 days) suffered an osteoporotic vertebral fracture were hospitalized for a period of 14 days. Salmon calcitonin (100 IU) or placebo injections were given daily. Pain was rated daily on a 10-point scale by the same observers. Blood and urinary parameters were also evaluated. The results showed a significant (P<0.001) difference in pain intensity between the calcitonin group and the placebo group. This beneficial effect was generally apparent from the second day of treatment onward, and over the following 2 weeks, the patients were able to sit and stand, and gradually started to walk again. A significant decrease in urinary hydroxyproline and urinary calcium was also noted in the calcitonin group. It is concluded that calcitonin exerts a beneficial effect on back pain following a vertebral crush fracture.
Similar content being viewed by others
References
Altman RD, Collins-Yudiskas B (1987) Synthetic human calcitonin in refractory Paget's disease of bone. Arch Intern Med 147:1305–1308
Gennari C, Chierichetti SM, Gonnelli S (1985) Analgesic activity and side effects of different calcitonins in man. In: Pecile A (ed) Calcitonin 1984—chemistry, physiology, pharmacology and clinical aspects. Excerpta Medica, Amsterdam, pp 183–188
Spaventi S, Vibanec D (1987) Effect of calcitonin on the skeleton and bone pain in patients with osteolytic metastases. Acta Med Yugosl 41:32–42
Doury P, Patin S (1980) Le traitement de l'algodystrophy par la Thyrocalcitonine. A propos de 60 observations. Rheumatologie 22:113–118
Gennari C (1987) Calcitonin in osteogenic pain. In: Christiansen C, Johansen JS, Riis BJ (eds) Intl Symp Osteoporosis. pp 1256–1261
Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB (1984) Long term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303
Lyritis GP (1984) Rotational administration of calcitonin for the treatment of postmenopausal osteoporosis. Calcitonin 1984. Intl Symp. Milan, p 107
Levernieux J, Julien D, Caulin F (1986) Double-blind study on the effect of calcitonin on pain and acute resorption related to recent osteoporotic crush fractures. In: Doepfner (ed) Calcitonin 1984: selected short communications. Intl Calcitonin Symp Milan 2–4 October 1984. Excerpta Medica, Amsterdam
Lam KS (1988) Clinical evaluation of short-term Miacalcic (synthetic salmon calcitonin) in osteoporotic bone pain. In: Chestnut (ed) Osteoporosis—epidemiology, clinical presentation, diagnosis and treatment. Excerpta Medica Asia Ltd, Hong-Kong pp 81–86
Pun KK, Chan MB (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin ther 11:205–209
Lyritis GP, Mayasis B, Tsakalakos N, Lambropoulos A, Gazi S, Karachalios Th, Tsekoura M, Yiatzides A The natural history of the osteoporotic vertebral fracture. Clin Rheumatol 8 (suppl) 2:66–69
Pecile A, Ferri S, Braga PC, Oliati VR (1975) Effects of intracerebroventricular calcitonin in the concious rabbit. Experimentia 31:332–333
Mirales FS, Lopez-Soriano F, Puig MM (1987) Postoperative analgesia induced by subarachnoid lidocain plus calcitonin. Anesth Analg 66:615–618
Fraioli F, Fabbri A, Gnessi L, Moretti S, Santoro C, Felici M (1982) Subarachnoid injection of salmon calcitonin induces analgesia in man. Eur J Pharmacol 78:381–382
Miller ME, Allgower M, Schneider R, Willeneger H (1979) Manual of internal fixation. Springer Verlag, New York, p 3
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lyritis, G.P., Tsakalakos, N., Magiasis, B. et al. Analgesic effect of Salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study. Calcif Tissue Int 49, 369–372 (1991). https://doi.org/10.1007/BF02555844
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02555844